DLC-50

• Description :

  DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC50 of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; HDAC; PARP

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/dlc-50.html

• Smiles :

  O=C1NN=C(CC2=CC=C(F)C(C(N3CCN(C(SCCCCCCC(NO)=O)=S)CC3)=O)=C2)C4=CC=CC=C41

• Molecular Formula :

  C28H32FN5O4S2

• Molecular Weight :

  585.71

• References & Citations :

  [1]Wu J, et al. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors[J]. Bioorganic Chemistry, 2024: 107556.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; PARP1

• CAS Number :

  [2928537-98-6]